Strata Critical Medical Reports Strong Q4, Raises 2026 Revenue & EBITDA Guidance

summarizeSummary

Strata Critical Medical announced robust fourth-quarter 2025 financial results, including significant revenue and Adjusted EBITDA growth, and raised its full-year 2026 guidance.

check_boxKey Events

• Strong Q4 2025 Performance

  Total revenue increased 83.5% year-over-year to $66.8 million, with Logistics revenue growing 35.3%. Adjusted EBITDA surged 547% to $7.0 million.

• Full-Year 2025 Exceeds Guidance

  Full-year 2025 Adjusted EBITDA of $14.1 million surpassed the high end of the company's guidance range.

• Raised 2026 Financial Outlook

  The company increased its full-year 2026 revenue guidance to $260-$275 million and Adjusted EBITDA guidance to $29-$33 million.

• Enhanced Liquidity and Strategic Growth

  Strata closed a new $30 million asset-backed credit facility and continues to expand its organ recovery platform and aircraft fleet, supporting future growth initiatives.

auto_awesomeAnalysis

Strata Critical Medical demonstrated strong operational momentum with an 83.5% year-over-year increase in Q4 revenue and a 547% surge in Adjusted EBITDA, exceeding prior guidance. The raised 2026 revenue and Adjusted EBITDA outlook, coupled with the successful integration of the Keystone acquisition and a new $30 million credit facility, signals continued growth and improved financial health. Investors should view this as a strong indicator of the company's execution and future potential in the critical medical logistics sector.